Condition:   Hepatitis C Virus
Interventions:   Biological: Peginterferon Lambda-1a;   Biological: Peginterferon Alfa-2a;   Drug: Ribavirin;   Drug: Telaprevir
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Not yet recruiting - verified May 2012

Condition:   Hepatitis B
Interventions:   Drug: Entecavir;   Drug: Peginterferon alfa-2a
Sponsors:   Sun Yat-sen University;   Sun Yat-sen University
Not yet recruiting - verified May 2012

Condition:   Chronic Viral Hepatitis B Without Delta-agent
Interventions:   Drug: Telbivudine;   Drug: Entecavir
Sponsors:   Asan Medical Center;   Asan Medical Center
Not yet recruiting - verified May 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: Group A (Zeffix, Sebivo, Hepsera);   Drug: Group B (Baraclude, Viread)
Sponsors:   Yonsei University;   Yonsei University;   Bristol-Myers Squibb;   Asan Medical Center;   Seoul St. Mary's Hospital;   Soonchunhyang University Hospital;   Pusan National University Hospital;   Kyungpook National University;   Hallym University Medical Center;   Chonbuk National University Hospital
Not yet recruiting - verified May 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: Entecavir + Tenofovir (MDR group)
Sponsors:   Yonsei University;   Yonsei University;   Bristol-Myers Squibb;   Asan Medical Center;   Seoul St. Mary's Hospital
Not yet recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: MK-2748;   Drug: Placebo
Sponsors:   Merck;   Merck
Not yet recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: boceprevir;   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin (Copegus];   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin (Copegus]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified May 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: Pegalyted interferon, Entecavir
Sponsors:   Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh;   Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Recruiting - verified May 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: Boceprevir;   Drug: Peginterferon alpha-2b;   Drug: Ribavirin;   Drug: Boceprevir;   Drug: Peginterferon alfa-2b;   Drug: Ribavirin
Sponsors:   Schering-Plough;   Schering-Plough
Not yet recruiting - verified May 2012

Condition:   Hepatitis b Vaccine
Intervention:  
Sponsors:   Medical Corps, Israel Defense Force;   Medical Corps, Israel Defense Force
Recruiting - verified May 2012

Condition:   Hepatic Impairment
Intervention:   Drug: telaprevir
Sponsors:   Janssen Infectious Diseases BVBA;   Janssen Infectious Diseases BVBA
Not yet recruiting - verified May 2012

Conditions:   Hepatitis B;   HBV
Interventions:   Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified December 2011

Condition:   Hepatitis B
Interventions:   Drug: Single Ascending Dose (SAD) Cohorts GS-9620;   Drug: Multiple Ascending Dose (MAD) Cohorts GS-9620
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified December 2011

Condition:   Chronic Liver Disease
Intervention:   Drug: Perfusion MRI (adofosveset trisodium, Ablavar, Lantheus)
Sponsors:   Mount Sinai School of Medicine;   Bachir Taouli
Recruiting - verified May 2012

Conditions:   Hepatitis C;   Liver Transplant Recipient
Interventions:   Drug: Peginterferon alfa-2a;   Drug: Ribavirin;   Drug: telaprevir
Sponsors:   University of Chicago;   University of Chicago
Recruiting - verified May 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: Telbivudine;   Drug: Tenofovir;   Drug: Entecavir
Sponsors:   Pusan National University Yangsan Hospital;   Pusan National University Yangsan Hospital
Recruiting - verified April 2012

Conditions:   Hepatitis C Virus;   Liver Transplant Recipient;   Recurrent Fibrosis
Interventions:   Drug: Rifaximin;   Drug: Placebo
Sponsors:   Columbia University;   Columbia University
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Biological: Pegasys;   Biological: P1101, 48 doses;   Biological: P1101, 24 doses;   Biological: P1101, 12 doses
Sponsors:   PharmaEssentia;   PharmaEssentia
Recruiting - verified April 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: ribavirin [Copegus];   Drug: peginterferon alfa-2a [Pegasys]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified April 2012

Condition:   Chronic Hepatitis C Infection
Interventions:   Drug: Panel 1: JNJ-47910382;   Drug: Panel 1: Placebo;   Drug: Panel 2: JNJ-47910382;   Drug: Panel 2: Placebo;   Drug: Panel 3: JNJ-47910382;   Drug: Panel 3: Placebo;   Drug: Panel 4: JNJ-47910382;   Drug: Panel 4: Placebo
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Not yet recruiting - verified April 2012

Conditions:   Chronic Hepatitis B e Antigen Positive;   Chronic Hepatitis B e Antigen Negative
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012

Condition:   Hepatitis C
Interventions:   Drug: TMC647055;   Drug: TMC647055;   Drug: TVR;   Drug: TVR;   Drug: TVR;   Drug: PegFN;   Drug: RBV
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified May 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   Johnson & Johnson Medical, China;   Johnson & Johnson Medical, China
Recruiting - verified May 2012

Condition:   Hepatitis C Virus
Interventions:   Drug: Asunaprevir (ASV);   Drug: Daclatasvir (DCV);   Drug: PBO matching ASV;   Drug: Placebo (PBO) matching DCV;   Drug: Pegylated-interferon alfa 2a (PegIFN);   Drug: Ribavirin (RBV)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Not yet recruiting - verified April 2012

Condition:   Hepatitis C
Intervention:   Drug: Boceprevir
Sponsors:   University of Calgary;   University of Calgary;   Merck
Not yet recruiting - verified April 2012

Condition:   Chronic Hepatitis C Virus
Interventions:   Drug: VX-222;   Drug: telaprevir;   Drug: ribavirin
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Not yet recruiting - verified April 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: RO5024048;   Drug: RO5024048;   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin [Copegus];   Drug: danoprevir;   Drug: ritonavir
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified May 2012

Condition:   Chronic Hepatitis C Infection
Interventions:   Drug: Valacyclovir;   Drug: Placebo
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   GlaxoSmithKline
Recruiting - verified April 2012

Condition:   Chronic Hepatitis C
Intervention:  
Sponsors:   Association HGE CHU Bordeaux Sud;   Association HGE CHU Bordeaux Sud
Recruiting - verified March 2012

Condition:   Hepatitis C
Interventions:   Drug: BI 201335 high dose;   Drug: BI 201335 high dose;   Drug: BI 201335 high dose;   Drug: BI201335 low dose
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: BI 201335;   Drug: BI 201335
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Hepatitis C Virus
Interventions:   Drug: Asunaprevir;   Drug: Daclatasvir;   Drug: Peg-interferon Alfa-2a;   Drug: Ribavirin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Not yet recruiting - verified April 2012

Condition:   Hepatitis C Virus Infection, Response to Therapy of
Intervention:   Behavioral: Personalized Physical Activity and Psycho-Education (PPAPE) Program
Sponsors:   National Taiwan University Hospital;   National Taiwan University Hospital;   National Health Research Institutes, Taiwan
Recruiting - verified April 2012

Conditions:   Malignancy;   Hepatitis B
Interventions:   Drug: Entecavir;   Drug: Lamivudine
Sponsors:   Seoul National University Hospital;   Seoul National University Hospital
Not yet recruiting - verified April 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   Peking University People's Hospital;   Peking University People's Hospital;   Bristol-Myers Squibb
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: BI 201335;   Drug: Ethinylestradiol;   Drug: Ethinylestradiol;   Drug: levonorgestrel;   Drug: levonorgestrel
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Vitamin A Deficiency
Interventions:   Dietary Supplement: retinyl palmitate;   Dietary Supplement: Placebo
Sponsors:   USDA, Western Human Nutrition Research Center;   USDA, Western Human Nutrition Research Center;   International Centre for Diarrhoeal Disease Research, Bangladesh;   World Health Organization
Recruiting - verified April 2012

Conditions:   Hepatitis C;   HIV
Interventions:   Drug: PSI-7977;   Drug: Efavirenz;   Drug: Tenofovir;   Drug: Emtricitabine;   Drug: Atazanavir plus Ritonavir;   Drug: Zidovudine;   Drug: Lamivudine
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   Hepatitis C
Interventions:   Drug: Single Ascending Dose Cohorts GS-9620;   Drug: Multiple Ascending Dose Cohorts GS-9620
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified December 2011

Condition:   Vaccination; Complications, Reaction, Serum
Intervention:   Biological: hepatitis B vaccine
Sponsors:   Centers for Disease Control and Prevention, China;   Wu Jiang;   Beijing Municipal Science & Technology Commission
Recruiting - verified March 2012

Condition:   Hepatitis B
Intervention:   Other: Renal Safety Surveillance
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: MK-8325;   Drug: Placebo
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: ALS-002158;   Drug: Placebo
Sponsors:   Alios Biopharma Inc.;   Alios Biopharma Inc.;   Vertex Pharmaceuticals Incorporated
Recruiting - verified March 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: ALS-002200;   Drug: Placebo
Sponsors:   Alios Biopharma Inc.;   Alios Biopharma Inc.;   Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: Switching from adefovir (10mg/day) to tenofovir (300mg/day)
Sponsors:   Yonsei University;   Yonsei University
Recruiting - verified May 2012

Condition:   Chronic Hepatitis B Virus Treatment
Intervention:  
Sponsors:   Ain Shams University;   Ain Shams University
Recruiting - verified March 2012

Conditions:   Hepatitis C;   Hepatocellular Carcinoma
Intervention:   Drug: GS-7977+RBV
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Condition:   Hepatitis C
Intervention:   Drug: Sitagliptin
Sponsors:   Institut National de la Santé Et de la Recherche Médicale, France;   Institut National de la Santé Et de la Recherche Médicale, France
Not yet recruiting - verified March 2012

Conditions:   Hepatitis C;   Hypertension
Interventions:   Drug: Amlodipine;   Drug: Diltiazem
Sponsors:   Ottawa Hospital Research Institute;   Ottawa Hospital Research Institute;   Merck
Not yet recruiting - verified March 2012

Condition:   Hepatitis C, Chronic
Interventions:   Biological: peginterferon alfa-2a;   Drug: ribavirin;   Drug: boceprevir
Sponsors:   Schering-Plough;   Schering-Plough
Not yet recruiting - verified May 2012

Condition:   Chronic Hepatitis C
Intervention:  
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified March 2012

Condition:   Hepatitis
Intervention:   Drug: MK-5172
Sponsors:   Merck;   Merck
Not yet recruiting - verified April 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: Ypeginterferon alfa-2b;   Drug: Pegasys;   Drug: Ypeginterferon alfa-2b;   Drug: Pegasys
Sponsors:   Xiamen Amoytop Biotech Co., Ltd.;   Xiamen Amoytop Biotech Co., Ltd.
Recruiting - verified April 2012

Conditions:   Hepatitis B;   Chronic Hepatitis B e Antigen Positive
Intervention:   Drug: Entecavir/Peginterferon
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012

Condition:   Hepatitis C Infection
Intervention:   Drug: ITX 5061
Sponsors:   Schiano, Thomas D., MD;   Schiano, Thomas D., MD;   iTherX Pharma, Inc.
Not yet recruiting - verified March 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   Institut National de la Santé Et de la Recherche Médicale, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: Nucleos(t)ide analogue treatment and add-on of peginterferon for 24 weeks
Sponsors:   Foundation for Liver Research;   Foundation for Liver Research
Not yet recruiting - verified April 2012

Condition:   Hepatitis C Infection
Interventions:   Biological: MBL-HCV1;   Drug: Telaprevir
Sponsors:   MassBiologics;   MassBiologics
Not yet recruiting - verified April 2012

Condition:   Hepatitis, Viral, Human
Interventions:   Drug: MK-8742;   Drug: Placebo
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Conditions:   Hepatitis C, Chronic;   Non-Alcoholic Fatty Liver Disease
Intervention:   Device: Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)
Sponsors:   HepQuant, LLC;   HepQuant, LLC
Recruiting - verified April 2012

Condition:   Inflammatory Bowel Disease
Interventions:   Biological: ENGERIX-B (HBV Vaccine);   Biological: Sci-B-Vac
Sponsors:   Soroka University Medical Center;   Soroka University Medical Center
Not yet recruiting - verified April 2012

Condition:   Chronic Hepatitis B
Intervention:  
Sponsors:   Yonsei University;   Yonsei University
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Ribavirin;   Drug: Ribavirin;   Drug: BI 207127 NA;   Drug: BI 207127 NA;   Drug: BI 201335 NA;   Drug: BI 201335 NA;   Drug: peginterferon;   Drug: peginterferon
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Hepatitis C Chronic
Intervention:  
Sponsors:   Schering-Plough;   Schering-Plough
Not yet recruiting - verified April 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: Peg-Interferon;   Procedure: Liver Samples from FNA;   Procedure: Liver Samples from CNB;   Procedure: Blood Samples;   Drug: Ribavarin;   Drug: 800 mg MK-5172;   Drug: 100 mg MK-5172;   Procedure: Liver samples from CNB and FNA
Sponsors:   Merck;   Merck
Not yet recruiting - verified March 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: tenofovir;   Drug: ribavirin;   Drug: ribavirin;   Drug: ribavirin;   Drug: caffeine;   Drug: caffeine;   Drug: midazolam;   Drug: midazolam;   Drug: tolbutamide;   Drug: tolbutamide;   Drug: pegylated inteferon;   Drug: pegylated interferon;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 207127;   Drug: BI 207127;   Drug: BI 207127
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Other Condition That May be a Focus of Clinical Attention
Intervention:   Biological: Vaccination against hepatitis A
Sponsors:   Federal University of São Paulo;   Federal University of São Paulo;   Fundação de Amparo à Pesquisa do Estado de São Paulo;   AFIP: Associação Fundo de Incentivo à Pesquisa
Not yet recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: pegylated Interferon-alpha 2a
Sponsors:   Yonsei University;   Yonsei University
Recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: Pegylated interferon alfa-2a plus nucleos(t)ide(s)
Sponsors:   Johannes Gutenberg University Mainz;   Johannes Gutenberg University Mainz;   Roche Pharma AG
Not yet recruiting - verified April 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: BMS-929075;   Drug: BMS-929075;   Drug: BMS-929075;   Drug: BMS-929075;   Drug: Placebo matching BMS-929075;   Drug: Placebo matching BMS-929075
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Not yet recruiting - verified January 2012

Condition:   Chronic Hepatitis C Infection
Interventions:   Drug: Valacyclovir;   Drug: Placebo
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   GlaxoSmithKline
Recruiting - verified January 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: tenofovir disoproxil fumarate 300mg per day;   Drug: Placebo
Sponsors:   E-DA Hospital;   E-DA Hospital;   Gilead Sciences;   Taipei Institute of Pathology, Taiwan
Recruiting - verified May 2012

Condition:   Hepatitis B, Chronic
Intervention:   Drug: Telbivudine, Adefovir dipivoxil
Sponsors:   Third Affiliated Hospital, Sun Yat-Sen University;   Third Affiliated Hospital, Sun Yat-Sen University;   Guangdong Provincial People's Hospital;   Guangzhou 8th People's Hospital
Recruiting - verified January 2012

Condition:   Hepatitis C
Intervention:   Drug: TMC435
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Condition:   Hepatitis C Virus Recurrence
Interventions:   Drug: Silibinin (Legalon-SIL);   Drug: Saline
Sponsors:   Rottapharm;   Rottapharm;   Azienda Ospedaliera Universitaria Policlinico
Recruiting - verified January 2012

Conditions:   Hepatitis C;   HCV
Intervention:  
Sponsors:   University of Cincinnati;   University of Cincinnati;   Merck
Recruiting - verified January 2012

Condition:   Chronic Hepatitis C
Intervention:  
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified January 2012

Conditions:   Genotype 1 Chronic Hepatitis C;   Treatment naïve With HCV-1/HIV-1 Coinfection;   Treatment Experienced With HCV-1/HIV-1 Coinfection
Interventions:   Drug: Telaprevir;   Drug: Pegylated Interferon alfa-2a;   Drug: Ribavirin
Sponsors:   Tibotec BVBA;   Tibotec BVBA
Not yet recruiting - verified January 2012

Condition:   Hepatitis B Virus Recurrence
Intervention:   Drug: Hepabulin IV
Sponsors:   SK Chemicals Co.,Ltd.;   SK Chemicals Co.,Ltd.
Recruiting - verified December 2011

Condition:   Chronic Hepatitis C Virus
Interventions:   Drug: VX-222;   Drug: telaprevir;   Drug: ribavirin;   Biological: peginterferon-alfa-2a
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified January 2012

Condition:   HCV Infection
Interventions:   Drug: ABT-267;   Drug: ABT-450/r;   Drug: ABT-333;   Drug: Ribavirin (RBV)
Sponsors:   Abbott;   Abbott
Recruiting - verified May 2012

Condition:   Hepatitis C
Intervention:   Drug: BMS-914143
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Hepatitis C
Interventions:   Drug: Telaprevir + peginterferon alfa + ribavirin;   Drug: peginterferon alfa + ribavirin;   Drug: peginterferon alfa + ribavirin
Sponsors:   Janssen-Cilag International NV;   Janssen-Cilag International NV
Available - verified April 2012

Conditions:   Chronic Hepatitis C;   Liver Cirrhosis
Intervention:   Drug: keyhole-limpet hemocyanin
Sponsors:   Medical University of Graz;   Medical University of Graz
Recruiting - verified January 2012

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified February 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: IDX719 or matching placebo (oral suspension);   Drug: IDX719 or matching placebo (oral suspension)
Sponsors:   Idenix Pharmaceuticals;   Idenix Pharmaceuticals
Recruiting - verified January 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: telaprevir formulation A;   Drug: telaprevir Formulation B;   Drug: telaprevir Formulation C;   Drug: telaprevir Formulation D
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified March 2012

Conditions:   Hepatitis B;   Renal Failure With Tubular Necrosis
Intervention:   Biological: plasma and urine samples, sample with ADN
Sponsors:   University Hospital, Limoges;   University Hospital, Limoges
Recruiting - verified December 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Telaprevir;   Drug: Telaprevir
Sponsors:   Janssen-Cilag International NV;   Janssen-Cilag International NV
Recruiting - verified April 2012

Condition:   Hepatitis D
Intervention:   Drug: Lonafarnib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011

Conditions:   Treatment of Genotype 1 Chronic HCV;   Liver Transplantation
Interventions:   Drug: Telaprevir;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin
Sponsors:   Janssen-Cilag International NV;   Janssen-Cilag International NV
Recruiting - verified April 2012

Condition:   Liver Fibrosis
Intervention:   Device: Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens
Sponsors:   University Hospital, Grenoble;   University Hospital, Grenoble;   Clinical investigation center, Technological innovation
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Drug: BMS-790052 (Daclatasvir);   Drug: Telaprevir;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Conditions:   Depression;   Hepatitis c
Intervention:  
Sponsors:   Centro Hospitalar Lisboa Norte;   Centro Hospitalar Lisboa Norte
Not yet recruiting - verified December 2011

Condition:   Alcoholic Liver Disease
Intervention:   Drug: LACTOWELL
Sponsors:   Chuncheon Sacred Heart Hospital;   Chuncheon Sacred Heart Hospital
Recruiting - verified December 2011

Condition:   Hepatitis B, Chronic
Interventions:   Drug: peginterferon alfa-2a [Pegasys];   Drug: peginterferon alfa-2a [Pegasys]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: BMS-790052 (Daclatasvir);   Drug: BMS-650032 (Asunaprevir)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified January 2012

Conditions:   Hepatitis B Infection;   Chronic Infection;   Viremia
Interventions:   Drug: TDF for mothers, HBIG + HBV vaccine for infants;   Other: HBIG and HBV vaccine for infants
Sponsors:   New Discovery LLC;   New Discovery LLC;   Gilead Sciences
Recruiting - verified March 2012

Condition:   Hepatitis C
Intervention:   Drug: Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified April 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: danoprevir;   Drug: ritonavir;   Drug: RO5024048;   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: PSI-352938;   Drug: PSI-7977
Sponsors:   Pharmasset;   Pharmasset
Recruiting - verified December 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: mericitabine;   Drug: Placebo;   Drug: boceprevir;   Drug: boceprevir;   Drug: boceprevir;   Drug: Placebo;   Drug: Pegasys;   Drug: Copegus;   Drug: Pegasys;   Drug: Copegus
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: mericitabine;   Drug: mericitabine;   Drug: Placebo;   Drug: Placebo;   Drug: Pegasys;   Drug: Copegus;   Drug: Pegasys;   Drug: Copegus;   Drug: telaprevir
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   HIV Infections;   Hepatitis C
Interventions:   Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: TMC435;   Drug: TVR
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: GSK548470 300 mg tablet;   Drug: ETV 0.5 mg capsule
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Hepatitis B, Chronic
Intervention:   Drug: GSK548470 300 mg tablet
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified April 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   University of Florida
Recruiting - verified November 2011

Conditions:   Bacterial Infections;   Virus Diseases
Interventions:   Biological: V419;   Biological: Rotavirus vaccine;   Biological: Prevenar 13;   Biological: INFANRIX hexa
Sponsors:   Sanofi Pasteur MSD;   Sanofi Pasteur MSD;   Merck
Recruiting - verified May 2012

Condition:   Acute Alcoholic Hepatitis
Interventions:   Biological: ELAD (Extracorporeal Liver Assist System);   Biological: Standard of care only
Sponsors:   Vital Therapies, Inc.;   Vital Therapies, Inc.
Not yet recruiting - verified November 2011

Condition:   Hepatitis C, Genotype 1
Interventions:   Drug: BMS-790052 (Daclatasvir);   Drug: Ribavirin;   Drug: Peg-Interferon alfa 2a
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified April 2012

Condition:   Hepatitis C
Intervention:   Drug: Sildenafil and Boceprevir
Sponsors:   Imperial College London;   Imperial College London
Not yet recruiting - verified December 2011

Condition:   Hepatitis C
Interventions:   Drug: Telaprevir;   Drug: Ribavirin;   Biological: peginterferon alfa-2a
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: Telaprevir;   Drug: ribavirin;   Drug: peginterferon alfa-2a
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Drug: Telaprevir;   Drug: ribavirin;   Biological: peginterferon alfa-2a;   Drug: ribavirin;   Biological: peginterferon alfa-2a;   Drug: ribavirin;   Biological: peginterferon alfa-2a
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012

Condition:   Hepatitis C Infection
Intervention:   Drug: Boceprevir
Sponsors:   Arrowhead Regional Medical Center;   Arrowhead Regional Medical Center
Recruiting - verified November 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: MP-424 (generic name:Telaprevir);   Drug: Ribavirin;   Drug: Peginterferon alfa-2b
Sponsors:   Mitsubishi Tanabe Pharma Corporation;   Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: MP-424 (generic name:Telaprevir);   Drug: Ribavirin;   Drug: Peginterferon alfa-2b
Sponsors:   Mitsubishi Tanabe Pharma Corporation;   Mitsubishi Tanabe Pharma Corporation
Recruiting - verified November 2011

Conditions:   Renal Allograft;   Hepatitis C
Interventions:   Drug: Everolimus;   Drug: Cyclosporine;   Drug: Tacrolimus
Sponsors:   Irmandade Santa Casa de Misericórdia de Porto Alegre;   Irmandade Santa Casa de Misericórdia de Porto Alegre;   NOVARTIS BIOCIÊNCIAS S.A.
Recruiting - verified January 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: Pegylated interferon alfa-2a
Sponsors:   Beijing Ditan Hospital;   Beijing Ditan Hospital
Recruiting - verified November 2011

Condition:   Depression
Interventions:   Drug: Mirtazapine;   Other: Supportive psychotherapy
Sponsors:   Seoul National University Boramae Hospital;   Seoul National University Boramae Hospital
Recruiting - verified October 2011

Condition:   Hepatitis B
Intervention:  
Sponsors:   Public Health Service of Amsterdam;   Public Health Service of Amsterdam;   UMC Utrecht
Recruiting - verified November 2011

Condition:   Chronic Hepatitis B
Interventions:   Drug: Tenofovir disoproxil fumarate;   Drug: Lamivudine plus adefovir
Sponsors:   Taipei Veterans General Hospital,Taiwan;   Taipei Veterans General Hospital,Taiwan
Not yet recruiting - verified December 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: telaprevir;   Drug: Peginterferon alfa-2a;   Drug: ribavirin
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: anti-CD3 monoclonal antibody;   Drug: Sodium Chloride placebo
Sponsors:   Inspira Medical AB;   Inspira Medical AB;   NasVax Ltd
Not yet recruiting - verified October 2011

Conditions:   Hepatitis;   Tuberculosis
Intervention:  
Sponsors:   All India Institute of Medical Sciences, New Delhi;   All India Institute of Medical Sciences, New Delhi
Recruiting - verified February 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: BMS-650032;   Drug: BMS-650032;   Drug: BMS-790052;   Drug: BMS-790052;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified November 2011

Condition:   Hepatitis B, Chronic
Interventions:   Drug: Peginterferon alfa-2a;   Drug: Entecavir
Sponsors:   Gangnam Severance Hospital;   Gangnam Severance Hospital;   Roche Pharma AG
Not yet recruiting - verified October 2011

Condition:   Chronic Hepatitis C
Intervention:  
Sponsors:   Inje University;   Inje University
Recruiting - verified October 2011

Condition:   Hepatitis C
Interventions:   Drug: Armodafinil;   Drug: Placebo
Sponsors:   Research Foundation for Mental Hygiene;   Research Foundation for Mental Hygiene;   Mount Sinai School of Medicine;   Weill Medical College of Cornell University
Recruiting - verified November 2011

Condition:   Hepatitis B
Intervention:   Biological: Twinrix
Sponsors:   University of Aarhus;   University of Aarhus;   Aarhus University Hospital;   Monash Medical Centre
Not yet recruiting - verified October 2011

Conditions:   Chronic Hepatitis C;   Menopause
Intervention:   Drug: Pegylated Interferon, Ribavirin, Boceprevir
Sponsors:   University of Modena and Reggio Emilia;   University of Modena and Reggio Emilia;   Merck
Not yet recruiting - verified October 2011

Condition:   Chronic Hepatitis C Infection
Interventions:   Drug: Valacyclovir;   Drug: Placebo
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   GlaxoSmithKline
Recruiting - verified March 2012

Conditions:   Poliomyelitis;   Haemophilus Influenzae Type b Disease;   Hepatitis B;   Diphtheria;   Pertussis;   Tetanus
Interventions:   Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation A;   Biological: Combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b vaccine (GSK217744) - Formulation B;   Biological: Infanrix hexaTM;   Biological: Pfizer's 13-valent pneumococcal polysaccharide conjugate vaccine (Prevenar 13®)
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified February 2012

Condition:   Hepatitis C
Interventions:   Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Placebo matching BMS-790052;   Drug: Pegylated-interferon alfa 2a;   Drug: Pegylated-interferon alfa 2a;   Drug: Ribavirin;   Drug: Ribavirin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: PPI-668;   Drug: Placebo
Sponsors:   Presidio Pharmaceuticals, Inc.;   Presidio Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Healthy
Interventions:   Drug: TG-2349;   Drug: placebo
Sponsors:   TaiGen Biotechnology Co., Ltd.;   TaiGen Biotechnology Co., Ltd.
Recruiting - verified January 2012

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified January 2012

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified January 2012

Condition:   Vaccine Response Impaired
Interventions:   Biological: hepatitis A vaccine;   Biological: hepatitis A vaccine
Sponsors:   Sormland County Council, Sweden;   Sormland County Council, Sweden
Recruiting - verified October 2011

Conditions:   Hepatitis;   HIV/AIDS
Interventions:   Drug: Boceprevir;   Drug: Peg-Interferon-alfa 2B;   Drug: Ribavirin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Condition:   Sino-implant (II)
Intervention:   Drug: Sino-implant (II)
Sponsors:   FHI 360;   FHI 360;   Bill and Melinda Gates Foundation
Recruiting - verified May 2012

Condition:   Contraception
Intervention:  
Sponsors:   FHI 360;   FHI 360;   United States Agency for International Development (USAID)
Not yet recruiting - verified October 2011

Conditions:   HIV Infection;   Hepatitis C
Intervention:   Behavioral: Contigent voucher incentive (CVI)
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified October 2011

Conditions:   Hepatitis C;   Medication Adherence
Interventions:   Other: enhanced DOT (both pegylated interferon alfa-2a and ribavirin);   Other: standard DOT (PEG-DOT control arm)
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   Albert Einstein College of Medicine of Yeshiva University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2011

Condition:   Hepatitis C
Interventions:   Drug: 200 mg INX-08189 Fasted;   Drug: Placebo QD Fasted;   Drug: 100 mg INX-08189 QD with ribavirin;   Drug: Placebo QD with ribavirin;   Drug: 100 mg INX-08189 with low-fat meal;   Drug: Placebo with low-fat meal;   Drug: 100 mg INX-08189 BID Fasted;   Drug: Placebo BID Fasted
Sponsors:   Inhibitex;   Inhibitex
Recruiting - verified November 2011

Condition:   Renal Insufficiency
Intervention:   Drug: ATeGe-Fresenius
Sponsors:   Hospital Vall d'Hebron;   Hospital Vall d'Hebron;   Hospital Universitari Vall d'Hebron Research Institute
Recruiting - verified January 2012

Condition:   Hepatitis B
Intervention:  
Sponsors:   Beijing Municipal Science & Technology Commission;   Beijing Municipal Science & Technology Commission
Recruiting - verified September 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: Peginterferon alfa2a;   Drug: Ribavirin;   Drug: Peginterferon alfa2a;   Drug: Ribavirin
Sponsors:   Third Affiliated Hospital, Sun Yat-Sen University;   Third Affiliated Hospital, Sun Yat-Sen University
Recruiting - verified May 2012

Condition:   Hepatitis C Virus
Interventions:   Drug: ABT-450/r;   Drug: ABT-267;   Drug: ribavirin
Sponsors:   Abbott;   Abbott
Recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Interventions:   Biological: HBV DNA vaccine;   Other: Placebo
Sponsors:   The 458 Hospital of Chinese PLA;   Fuqiang Yang
Recruiting - verified September 2011

Conditions:   Human Immunodeficiency Virus Infection;   Hepatitis C
Intervention:  
Sponsors:   G & W Laboratories Inc.;   G & W Laboratories Inc.;   Alquest;   SMART Biotech Ltd
Recruiting - verified October 2011

Condition:   Hepatitis B, Chronic
Interventions:   Drug: telbivudine (ROADMAP);   Drug: Telbivudine (Standard of Care)
Sponsors:   Nanfang Hospital of Southern Medical University;   Nanfang Hospital of Southern Medical University;   Major Science and Technology Special Project of China Eleventh Five-year;   Novartis
Recruiting - verified March 2012

Condition:   HIV
Intervention:   Biological: Sci-B-Vac
Sponsors:   Tel-Aviv Sourasky Medical Center;   Tel-Aviv Sourasky Medical Center;   SciGen, Israel, the vaccine manufacturer, will be providing 300 Sci-B-Vac doses
Not yet recruiting - verified October 2011

Condition:   Chronic Hepatitis C
Intervention:   Dietary Supplement: Vit D
Sponsors:   Hanyang University;   Hanyang University;   Roche Pharma AG
Not yet recruiting - verified September 2011

Condition:   Hepatitis C
Interventions:   Biological: AdCh3NSmut1;   Other: Placebo;   Biological: MVA-NSmut
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   Chronic Hepatitis C
Intervention:   Dietary Supplement: Quercetin
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles;   American Association for Cancer Research;   Tower Cancer Research Foundation;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011

Condition:   Chronic Hepatitis B
Interventions:   Drug: Adefovir Dipivoxil and polyene phosphatidylcholine;   Drug: Adefovir Dipivoxil
Sponsors:   Capital Medical University;   Jun Cheng;   Sanofi-Aventis;   Fujian Cosunter Pharmaceutical Co. Ltd
Not yet recruiting - verified September 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: 48-weeks course;   Drug: Ribavirin;   Drug: Peginterferon alfa2a;   Drug: Ribavirin
Sponsors:   Third Affiliated Hospital, Sun Yat-Sen University;   Third Affiliated Hospital, Sun Yat-Sen University
Recruiting - verified September 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin [Copegus]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Hepatitis C
Intervention:   Biological: implantation
Sponsors:   Medgenics Medical Israel Ltd.;   Medgenics Medical Israel Ltd.
Not yet recruiting - verified May 2011

Condition:   Hepatitis C
Intervention:   Biological: Subcutan implantation of autologus skin graft after ex-vivo treatment
Sponsors:   Medgenics Medical Israel Ltd.;   Medgenics Medical Israel Ltd.
Not yet recruiting - verified September 2011

Condition:   Hepatitis C
Intervention:   Genetic: Interleukin 28B genotype
Sponsors:   Henry Ford Health System;   Henry Ford Health System
Recruiting - verified September 2011

Condition:   Hepatitis C Virus
Interventions:   Drug: BMS-790052 (HCV NS5A Replication Co-factor Inhibitor);   Drug: BMS-650032 (HCV NS3 Protease Inhibitor);   Drug: Peginterferon alfa-2a;   Drug: Ribavirin;   Drug: Ribavirin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   Closter Pharma;   Closter Pharma
Not yet recruiting - verified August 2011

Condition:   Hepatitis C, Chronic
Intervention:   Drug: Boceprevir
Sponsors:   Schering-Plough;   Schering-Plough
Recruiting - verified April 2012

Conditions:   Hepatitis C;   HIV
Intervention:   Drug: boceprevir; etravirine
Sponsors:   University of Colorado, Denver;   University of Colorado, Denver
Recruiting - verified August 2011

Conditions:   HIV Infection;   Hepatitis C
Intervention:  
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Chronic Hepatitis;   Chronic Hepatitis C;   Chronic Alcoholic Hepatitis
Intervention:   Drug: High dose vitamin C
Sponsors:   Seoul National University Hospital;   Seoul National University Hospital
Not yet recruiting - verified August 2011

Condition:   Hepatitis C Virus
Intervention:   Drug: rimantadine
Sponsors:   The Leeds Teaching Hospitals NHS Trust;   The Leeds Teaching Hospitals NHS Trust;   Cancer Research UK
Not yet recruiting - verified July 2011

Condition:   Hepatitis C
Interventions:   Drug: Peginterferon alfa-2a;   Drug: Ribavirin;   Drug: telaprevir
Sponsors:   University of Vermont;   University of Vermont
Recruiting - verified January 2012

Conditions:   Hepatitis C;   Renal Cell Carcinoma;   Colorectal Cancer
Intervention:   Other: Hepatitis C testing
Sponsors:   Henry Ford Health System;   Henry Ford Health System;   Schering-Plough
Recruiting - verified June 2011

Conditions:   Liver Diseases, Alcoholic;   Alcoholism;   HIV;   Hepatitis C
Interventions:   Other: Integrated Stepped Care (ISC);   Other: Treatment as Usual
Sponsors:   Yale University;   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   Department of Veterans Affairs
Not yet recruiting - verified August 2011

Condition:   Chronic Hepatitis C
Intervention:   Drug: Boceprevir
Sponsors:   Azienda Ospedaliero-Universitaria di Parma;   Azienda Ospedaliero-Universitaria di Parma
Not yet recruiting - verified July 2011

Conditions:   Chronic Hepatitis C;   Genotype 1
Interventions:   Procedure: Educational Intervention;   Other: No Intervention
Sponsors:   Chronic Liver Disease Foundation;   Chronic Liver Disease Foundation;   Clinical Development Group
Recruiting - verified February 2012

Conditions:   Cancer;   Liver Cancer;   Hepatocellular Carcinoma
Interventions:   Drug: PI-88;   Other: Placebo
Sponsors:   Medigen Biotechnology Corporation;   Medigen Biotechnology Corporation
Recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Intervention:  
Sponsors:   Foundation for Liver Research;   Foundation for Liver Research
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: BI201335;   Drug: BI201335 24W;   Drug: PegIFN/RBV;   Drug: PegIFN/RBV
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline;   Pharmaceutical Product Development Clinical Research Organization (CRO)
Recruiting - verified February 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Boceprevir (BOC);   Drug: Placebo to boceprevir;   Drug: Peginterferon alfa-2b (PEG);   Drug: Ribavirin (RBV);   Drug: Cross-Over Boceprevir Treatment
Sponsors:   Schering-Plough;   Schering-Plough
Recruiting - verified April 2012

Condition:   Hepatitis C
Intervention:   Drug: MK-5172
Sponsors:   Merck;   Merck
Recruiting - verified March 2012

Condition:   Hepatitis C
Interventions:   Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Peg-Interferon Alfa-2a;   Drug: Ribavirin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Conditions:   Drug Use;   HIV;   Hepatitis C
Intervention:   Behavioral: Brief motivational intervention
Sponsors:   Rhode Island Hospital;   Rhode Island Hospital;   National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011

Conditions:   Underlying Liver Disease;   Hepatitis;   Fibrosis of Liver;   Cirrhosis With Suspicion of Liver Cancer;   Lesion on a Prior Ultrasound, CT or Outside MRI
Intervention:  
Sponsors:   University of Nebraska;   University of Nebraska
Recruiting - verified August 2011

Conditions:   Hepatitis;   Tuberculosis, Pulmonary
Intervention:   Drug: isoniazid, rifampin, pyrazinamide
Sponsors:   National Taiwan University Hospital;   National Taiwan University Hospital
Recruiting - verified July 2011

Conditions:   Liver Cirrhosis;   Chronic Hepatitis B
Intervention:   Drug: telbivudine
Sponsors:   The Fifth People's Hospital of Suzhou;   The Fifth People's Hospital of Suzhou
Recruiting - verified June 2011

Condition:   Chronic Hepatitis
Intervention:   Drug: Peginterferon alpha-2a + Ribavirin
Sponsors:   Casa Sollievo della Sofferenza IRCCS;   Casa Sollievo della Sofferenza IRCCS;   Casa di Cura Mater Dei;   IRCCS L. Spallanzani;   Ospedale Francesco Ferrari, Casarano;   Ospedale SS. Annunziata, Sassari;   IRCCS Policlinico S. Matteo;   Arcispedale S. Anna, Ferrara;   Azienda Ospedaliero-Universitaria, Catania;   Ospedale di Venosa;   Ospedale R. Dimiccoli, Barletta;   IRCCS De Bellis, Castellana;   USL Napoli 1;   Ospedale San Giuseppe Moscati, Avellino;   Cardarelli Hospital;   Ospedale Civile Vittorio Emanuele II, Bisceglie;   Azienda Ospedaliero-Universitaria Careggi;   Azienda Ospedaliera V. Cervello;   Ospedale Civile Spirito Santo;   Ospedale di Canosa di Puglia;   University of Palermo;   San Camillo Hospital, Rome;   Campus Bio-Medico University;   Ospedale Sandro Pertini, Roma;   Ospedali Riuniti, Foggia;   Ospedale SS. Annunziata, Taranto;   Ospedale di Mottola;   Ospedale Santa Caterina Novella, Galatina;   University of Florence;   Ospedale Valduce, Como;   University of Bari;   Azienda Ospedaliera, Siracusa;   Azienda Ospedaliera, Lucca
Recruiting - verified April 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: GS-5885, GS-9451, PEG , RBV;   Drug: PEG, RBV
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified February 2012

Condition:   Chronic Hepatitis
Interventions:   Drug: oral antiviral for HBV;   Drug: tenofovir disoproxil fumarate
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Chronic Hepatitis C
Intervention:   Drug: statin
Sponsors:   Bader, Ted, M.D.;   Bader, Ted, M.D.
Not yet recruiting - verified June 2011

Conditions:   Sustained Virologic Response;   IL28B Polymorphism
Interventions:   Drug: peginterferon alfa 2a (pegasys);   Drug: peginterferon alfa-2a (pegasys)
Sponsors:   The Catholic University of Korea;   The Catholic University of Korea;   Ulsan University Hospital;   NHIC Ilsan hospital;   Inje University;   Soonchunhyang University Hospital;   Yonsei University;   Chungnam National University;   Keimyung University;   Kyungpook National University;   Konyang University Hospital;   Inha University Hospital;   Hallym University Medical Center
Recruiting - verified October 2008

Condition:   Chronic Hepatitis B
Interventions:   Drug: Peginterferon alfa-2a;   Drug: Nucleos(t)ide analogue
Sponsors:   Foundation for Liver Research;   Foundation for Liver Research;   Hoffmann-La Roche
Not yet recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: HBsAg and HBcAg combination;   Drug: Peginterferon alfa-2b
Sponsors:   Clinical Research Organization, Dhaka, Bangladesh;   Clinical Research Organization, Dhaka, Bangladesh
Recruiting - verified June 2011

Condition:   Acute on Chronic Hepatic Failure
Interventions:   Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO);   Drug: Placebo
Sponsors:   Institute of Liver and Biliary Sciences, India;   Institute of Liver and Biliary Sciences, India
Recruiting - verified October 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: IDX184;   Drug: IDX184
Sponsors:   Idenix Pharmaceuticals;   Idenix Pharmaceuticals
Recruiting - verified February 2012

Condition:   Hepatitis B
Intervention:   Drug: Entecavir and peginterferon
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Pittsburgh
Not yet recruiting - verified May 2012

Condition:   Hepatitis B
Interventions:   Drug: Tenofovir;   Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Pittsburgh
Not yet recruiting - verified February 2012

Condition:   Hepatitis B
Interventions:   Other: Control Arm;   Drug: Entecavir and peginterferon
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified January 2012

Condition:   Hepatitis C, Chronic, Healthy Volunteer
Interventions:   Drug: RO5428029;   Drug: placebo
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Decompensated Cirrhosis;   Bleeding Varices
Interventions:   Procedure: Transjugular intrahepatic portosystemic shunt;   Drug: Non-selective beta blocker + Endoscopic treatment
Sponsors:   Fourth Military Medical University;   Fourth Military Medical University
Recruiting - verified May 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Pegylated interferon alfa 2b;   Drug: Ribavirin
Sponsors:   Kirby Institute;   Kirby Institute;   Merck
Not yet recruiting - verified May 2011

Conditions:   Cytomegalovirus Infection;   Hepatitis C
Intervention:  
Sponsors:   Sociedad Española de Trasplante Hepático;   Sociedad Española de Trasplante Hepático;   Roche Farma, S.A.
Recruiting - verified November 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: PSI-7977;   Drug: BMS-790052;   Drug: Ribavirin;   Drug: Ribavirin;   Drug: Ribavirin;   Drug: BMS-790052;   Drug: PSI-7977
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Pharmasset
Recruiting - verified January 2012

Condition:   Thrombocytopenia
Intervention:   Drug: E5501 (previously known as AKR-501 monomaleate)
Sponsors:   Eisai Inc.;   Eisai Inc.
Recruiting - verified November 2011

Conditions:   Diphtheria;   Hepatitis B;   Haemophilus Influenzae Type b Disease;   Poliomyelitis;   Pertussis;   Tetanus
Intervention:   Biological: Infanrix hexa™
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Not yet recruiting - verified April 2012

Conditions:   Hepatitis;   HIV;   Liver Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC);   Washington DC Veterans Affairs Medical Center
Recruiting - verified February 2012

Condition:   Hepatitis B
Interventions:   Biological: HepavaxGene (thiomersal free);   Biological: Engerix B
Sponsors:   Crucell Holland BV;   Crucell Holland BV
Recruiting - verified March 2012

Conditions:   Plasmodium Falciparum Malaria;   Hepatitis B
Interventions:   Biological: GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049;   Biological: Engerix-B vaccine;   Biological: Infanrix/Hib vaccine;   Biological: Polio Sabin vaccine;   Biological: Rotarix vaccine;   Biological: Synflorix vaccine;   Biological: Measles vaccine;   Biological: Yellow fever vaccine
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified November 2011

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified July 2011

Condition:   Hepatitis C
Intervention:   Other: Blood samples
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Conditions:   Liver Failure;   Hepatitis B
Intervention:   Drug: 5 days dexamethasone therapy
Sponsors:   Third Military Medical University;   Third Military Medical University
Recruiting - verified June 2011

Conditions:   Hepatitis B, Chronic;   Liver Fibrosis
Intervention:   Drug: Treatment with entecavir(Baraclude®)
Sponsors:   RWTH Aachen University;   RWTH Aachen University;   Hannover Medical School;   Hannover Clinical Trial Center GmbH
Not yet recruiting - verified March 2012

Condition:   Acute Hepatitis C
Interventions:   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
Sponsors:   Kirby Institute;   Kirby Institute
Not yet recruiting - verified April 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: ChronVac-C + SOC;   Drug: SOC
Sponsors:   ChronTech Pharma AB;   ChronTech Pharma AB;   Inovio Pharmaceuticals
Recruiting - verified October 2011

Conditions:   HIV;   Hepatitis C;   HIV and Hepatitis C Coinfection
Intervention:  
Sponsors:   University of Cincinnati;   University of Cincinnati;   Merck
Recruiting - verified January 2012

Condition:   Hepatitis C
Interventions:   Drug: PegIFN/RBV;   Drug: BI 201335
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: Therapeutic HBV vaccine, entecavir;   Drug: Empty liposome, entecavir
Sponsors:   Chongqing Jiachen Biotechnology Ltd.;   Chongqing Jiachen Biotechnology Ltd.;   Third Military Medical University
Recruiting - verified September 2011

Condition:   Contraceptive Usage
Intervention:  
Sponsors:   FHI 360;   FHI 360;   United States Agency for International Development (USAID)
Recruiting - verified August 2011

Condition:   Hepatitis C
Intervention:   Drug: TMC435
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Conditions:   HIV Coinfection;   Hepatitis C;   Hepatitis B;   Hepatotoxicity
Interventions:   Drug: Maraviroc;   Drug: Placebo
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Pfizer
Recruiting - verified May 2012

Conditions:   HIV;   Hepatitis C;   Hepatitis B;   Syphilis
Interventions:   Device: Rapid tests for HIV, HCV, HBV, and syphilis;   Device: HIV/HCV;   Device: HIV/syphilis;   Device: HIV only
Sponsors:   California State University, Long Beach;   California State University, Long Beach;   National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012

Conditions:   HIV;   Hepatitis C;   Syphilis;   Herpes Simplex Type II
Interventions:   Behavioral: MMT provider dosage training;   Behavioral: targeted counseling;   Other: national guidelines
Sponsors:   Centers for Disease Control and Prevention;   Centers for Disease Control and Prevention;   National Center for AIDS/STD Control and Prevention, China CDC
Recruiting - verified April 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: Stopping TDF therapy
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified November 2011

Condition:   Hepatitis C
Interventions:   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: BMS-790052 (NS5A Inhibitor);   Drug: Ribavirin (RBV);   Drug: BMS-650032 (NS3 Protease Inhibitor);   Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a);   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: Ribavirin (RBV);   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: Ribavirin (RBV);   Drug: BMS-790052 (NS5A Inhibitor);   Drug: BMS-650032 (NS3 Protease Inhibitor);   Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor);   Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor);   Drug: Placebo for Ribavirin (RBV);   Drug: Placebo for Ribavirin (RBV)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified April 2012

Conditions:   Chronic Hepatitis B e Antigen Positive;   Chronic Hepatitis B e Antigen Negative
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012

Condition:   Hepatitis B
Interventions:   Drug: Entecavir;   Drug: Entecavir, Adefovir;   Drug: Entecavir, Adefovir
Sponsors:   Nanfang Hospital of Southern Medical University;   Nanfang Hospital of Southern Medical University;   JiangSu Chia-Tai Tianqin Pharmacy Co.Ltd
Recruiting - verified March 2012

Condition:   Hepatitis C Infection
Interventions:   Biological: MVA-NSmut;   Biological: AdCh3NSmut; MVA-NSmut;   Biological: AdCh3NSmut; MVA-NSmut;   Biological: AdCh3NSmut ; MVA-NSmut;   Biological: AdCh3NSmut; MVA-NSmut
Sponsors:   Okairos;   Okairos;   University of Oxford;   Oxford University Hospitals NHS Trust;   University Hospital Birmingham
Recruiting - verified October 2011

Condition:   Healthy, no Evidence of Disease
Interventions:   Biological: hepatitis B antigen peptide;   Other: placebo;   Other: immunoenzyme technique
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
Not yet recruiting - verified January 2012

Condition:   Contraception
Intervention:   Drug: one of 5 products
Sponsors:   FHI 360;   FHI 360;   National Institutes of Health (NIH)
Recruiting - verified April 2012

Conditions:   HIV Infection;   Hepatitis C
Interventions:   Drug: Anti-HIV Agents;   Drug: raltegravir;   Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011

Condition:   Hepatitis B Virus Infection, Pregnancy
Intervention:   Drug: antiviral therapy
Sponsors:   National Taiwan University Hospital;   National Taiwan University Hospital
Recruiting - verified August 2011

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a;   Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a;   Drug: Tenofovir Disoproxil Fumarate;   Drug: Peginterferon α-2a
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   Chronic Hepatitis C
Intervention:  
Sponsors:   Avera McKennan Hospital & University Health Center;   Avera McKennan Hospital & University Health Center
Recruiting - verified January 2011

Condition:   Hepatitis C
Interventions:   Drug: TMC435;   Drug: Placebo
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: Placebo;   Drug: TMC435
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Drug: Placebo;   Drug: TMC435
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Condition:   Hepatitis C Virus
Intervention:   Drug: Insulin
Sponsors:   McGill University Health Center;   McGill University Health Center
Recruiting - verified August 2011

Condition:   Chronic Hepatitis B
Intervention:   Drug: telbivudine
Sponsors:   Yonsei University;   Yonsei University
Recruiting - verified January 2012

Condition:   Liver Fibrosis
Intervention:  
Sponsors:   China Medical University Hospital;   China Medical University Hospital
Recruiting - verified June 2011

Condition:   Hepatitis B
Intervention:  
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified June 2011

Condition:   Hepatitis B
Intervention:  
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011

Condition:   Chronic Hepatitis B
Interventions:   Drug: Tenofovir;   Drug: Telbivudine;   Drug: Tenofovir plus Telbivudine
Sponsors:   Institute of Liver and Biliary Sciences, India;   Institute of Liver and Biliary Sciences, India
Recruiting - verified June 2011

Condition:   Chronic Hepatitis C Infection
Interventions:   Drug: PSI-7977 in combination with RBV;   Drug: PSI-7977 in combination with RBV and PEG-IFN;   Drug: PSI-7977 in combination with RBV and PEG-IFN;   Drug: PSI-7977 in combination with RBV and PEG-IFN;   Drug: PSI-7977 monotherapy;   Drug: PSI-7977 in combination with RBV and PEG-IFN;   Drug: PSI-7977 in combination with RBV;   Drug: PSI-7977 in combination with RBV;   Drug: PSI-7977 in combination with RBV;   Drug: PSI-7977 in combination with RBV;   Drug: PSI-7977 in combination with 800 mg RBV;   Drug: PSI-7977 in combination with GS-5885 and RBV;   Drug: PSI-7977 in combination with RBV
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified February 2012

Condition:   Hepatitis C
Interventions:   Drug: Silymarin;   Drug: Placebo
Sponsors:   Bukwang Pharmaceutical;   Bukwang Pharmaceutical
Recruiting - verified October 2011

Condition:   Hepatitis C Infection
Interventions:   Drug: Placebo;   Drug: SCY-635;   Drug: SCY-635;   Drug: SCY-635;   Drug: peginterferon alfa 2a;   Drug: Ribavirin
Sponsors:   Scynexis Incorporated;   Scynexis Incorporated
Recruiting - verified June 2011

Conditions:   Hearing Loss;   Sudden Deafness
Intervention:  
Sponsors:   Carmel Medical Center;   Carmel Medical Center
Not yet recruiting - verified December 2010

Condition:   Chronic Hepatitis B
Intervention:   Drug: PEG-IFN and entecavir
Sponsors:   Chulalongkorn University;   Chulalongkorn University
Recruiting - verified June 2011

Conditions:   Hepatocellular Carcinoma;   Liver Cancer
Intervention:   Drug: bavituximab and sorafenib
Sponsors:   University of Texas Southwestern Medical Center;   University of Texas Southwestern Medical Center
Recruiting - verified October 2010

Condition:   Alcoholic Hepatitis
Intervention:  
Sponsors:   University of Aarhus;   University of Aarhus
Recruiting - verified March 2012

Conditions:   HIV;   Hepatitis C;   Liver Fibrosis
Interventions:   Drug: Raltegravir;   Drug: Ritonavir-boosted protease inhibitor
Sponsors:   McGill University Health Center;   McGill University Health Center;   Merck;   Canadian HIV Trials Network
Recruiting - verified March 2012

Condition:   Hepatitis B, Chronic
Interventions:   Drug: Entecavir and Pegylated interferon α-2a Sequential Treatment Group;   Drug: Pegylated interferon α-2a Monotreatment Group
Sponsors:   Hanyang University;   Hanyang University;   Roche Pharma AG
Recruiting - verified June 2011

Conditions:   Chronic HIV Infection;   HCV Coinfection
Intervention:   Drug: Fosamprenavir
Sponsors:   Fundacion SEIMC-GESIDA;   Fundacion SEIMC-GESIDA;   ViiV Healthcare
Recruiting - verified June 2011

Condition:   Hepatitis C
Intervention:   Drug: Interferon Alfa-2b
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   Tibotec Pharmaceutical Limited
Recruiting - verified February 2012

Condition:   Lymphoma
Intervention:   Drug: nucleoside analog reverse transcriptase inhibitor
Sponsors:   Fudan University;   Fudan University
Recruiting - verified September 2010

Conditions:   Human Immunodeficiency Virus (HIV);   Hepatitis C, Chronic
Intervention:  
Sponsors:   George Washington University;   George Washington University
Recruiting - verified September 2010

Condition:   Hepatitis B Virus
Interventions:   Drug: pegIFN;   Drug: pegIFNα-2a
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Intervention:   Device: 13C Methacetin Breath Test (BreathID)
Sponsors:   Hadassah Medical Organization;   Hadassah Medical Organization
Recruiting - verified June 2011

Condition:   Hepatitis B
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2012

Conditions:   Hepatitis C;   HIV
Intervention:   Drug: Pegylated interferon with ribavirin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID);   Fundacion de Investigacion de Diego
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Drug: Placebo;   Drug: Nitazoxanide
Sponsors:   National Liver Institute, Egypt;   National Liver Institute, Egypt
Recruiting - verified September 2011

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified September 2011

Conditions:   Hepatitis C Infection;   Thrombocytopenia
Interventions:   Biological: romiplostim;   Drug: ribavirin;   Other: placebo;   Biological: PEG-interferon alfa-2a;   Other: laboratory biomarker analysis
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012

Condition:   Hepatitis A
Intervention:  
Sponsors:   Rijnstate Hospital;   Rijnstate Hospital
Recruiting - verified June 2011

Conditions:   Hepatitis C;   Depression
Intervention:   Other: Depression collaborative care model
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Not yet recruiting - verified December 2011

Conditions:   HIV Infections;   Hepatitis;   Sexually Transmitted Infections
Interventions:   Behavioral: Traditional Prevention;   Behavioral: Web-based Prevention
Sponsors:   National Development and Research Institutes, Inc.;   National Development and Research Institutes, Inc.;   National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011

Condition:   Hepatorenal Syndrome Type 1
Interventions:   Drug: Terlipressin;   Drug: Placebo
Sponsors:   Ikaria Holdings Inc.;   Ikaria Holdings Inc.
Recruiting - verified May 2012

Condition:   Recurrent Hepatitis C After Liver Transplantation
Intervention:   Drug: mycophenolate to sirolimus switch
Sponsors:   London Health Sciences Centre;   London Health Sciences Centre
Recruiting - verified June 2011

Conditions:   Hepatitis B;   Liver Transplantation
Intervention:   Drug: Hepatitis B immune globulin
Sponsors:   Grifols Biologicals Inc.;   Instituto Grifols, S.A.
Recruiting - verified January 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: BI 207127;   Drug: BI 207127;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 201335;   Drug: Ribavirin;   Drug: Ribavirin;   Drug: BI 207127;   Drug: Ribavirin;   Drug: BI 207127;   Drug: Ribavirin;   Drug: Ribavirin;   Drug: BI 207127;   Drug: BI 207127;   Drug: Ribavirin;   Drug: Ribavirin;   Drug: BI 207127;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 207217;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 201335;   Drug: BI 207127;   Drug: Ribavirin;   Drug: Ribavirin;   Drug: BI 207127
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Conditions:   HIV Infections;   Hepatitis C
Interventions:   Drug: Raltegravir;   Drug: Atazanavir/Ritonavir
Sponsors:   St. James's Hospital;   St. James's Hospital
Recruiting - verified March 2010

Condition:   Chronic Hepatitis C - Genotype 3
Intervention:  
Sponsors:   University Health Network, Toronto;   University Health Network, Toronto
Recruiting - verified February 2010

Conditions:   Immunologic Tests;   Hepatitis B Infection
Intervention:   Other: Blood withdrawal
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified June 2011

Condition:   Hepatitis C Virus
Intervention:   Drug: ribavirin
Sponsors:   University of Colorado, Denver;   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011

Conditions:   HIV;   Hepatitis B
Interventions:   Drug: Tenofovir/lamivudine/lopinavir-ritonavir;   Drug: Zidovudine/lamivudine/lopinavir-ritonavir
Sponsors:   Centers for Disease Control and Prevention;   Centers for Disease Control and Prevention;   National Center for AIDS/STD Control and Prevention, China CDC
Not yet recruiting - verified October 2011

Condition:   Hepatitis C
Interventions:   Biological: AdCh3NSmut; Ad6NSmut;   Biological: AdCh3NSmut; Ad6NSmut;   Biological: AdCh3NSmut; Ad6NSmut;   Biological: AdCh3NSmut; Ad6NSmut;   Biological: AdCh3NSmut; Ad6NSmut;   Biological: AdCh3NSmut; Ad6NSmut;   Biological: AdCh3NSmut; Ad6NSmut;   Biological: AdCh3NSmut ; Ad6NSmut;   Biological: AdCh3NSmut; Ad6NSmut
Sponsors:   Okairos;   Okairos;   University of Oxford
Recruiting - verified October 2011

Condition:   Hepatitis B, Chronic
Intervention:  
Sponsors:   Johann Wolfgang Goethe University Hospitals;   Johann Wolfgang Goethe University Hospitals
Recruiting - verified May 2012

Condition:   Kidney-transplant Recipients With Chronic Hepatitis E Virus Infection
Interventions:   Other: blood samples;   Other: blood samples
Sponsors:   Assistance Publique Hopitaux De Marseille;   Assistance Publique Hopitaux De Marseille
Recruiting - verified April 2012

Conditions:   Liver Fibrosis;   Liver Cirrhosis;   Viral Hepatitis;   Liver Tumour;   Cardiac Failure;   Biliary Cholestasis.
Interventions:   Device: ARFI measurement;   Device: ARFI measurement;   Device: ARFI measurement
Sponsors:   University Hospital, Bordeaux;   University Hospital, Bordeaux
Recruiting - verified December 2011

Condition:   Chronic Hepatitis B Virus, Pediatric
Interventions:   Drug: Entecavir;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Conditions:   Cervical Neoplasia;   HPV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Primary Sclerosing Cholangitis
Intervention:   Drug: ursodeoxycholic acid (UDCA) withdrawal and reinstitution
Sponsors:   University of Tennessee;   University of Tennessee;   Mount Sinai School of Medicine;   Children's Memorial Hospital;   University of Colorado, Denver;   University of California, San Francisco;   University of Pittsburgh;   Children's Hospital Medical Center, Cincinnati;   Phoenix Children's Hospital
Recruiting - verified February 2012

Conditions:   Hepatitis;   Cytokines;   Pregnancy
Intervention:  
Sponsors:   Maulana Azad Medical College;   Maulana Azad Medical College;   Indian Council of Medical Research
Recruiting - verified July 2011

Conditions:   Chronic Renal Failure;   Humoral Immune Alterations
Interventions:   Procedure: High flux polymethylmetacrylate membrane;   Procedure: Polysulfone membrane;   Biological: Hepatitis B serological control;   Biological: Seric sCD40 level
Sponsors:   University Hospital, Bordeaux;   University Hospital, Bordeaux
Recruiting - verified November 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: Peginterferon alfa-2a and Ribavirin;   Drug: Peginterferon alfa-2a and Ribavirin
Sponsors:   Pusan National University Yangsan Hospital;   Pusan National University Yangsan Hospital;   Severance Hospital;   Pusan National University Hospital;   Incheon St.Mary's Hospital;   Soon Chun Hyang University Bucheon Hospital;   Inje University;   Inje University Ilsan Paik Hospital;   Inje University Haeundae Paik Hospital
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Other: Ribavrin;   Drug: Abacavir plus Ribavirin
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   GlaxoSmithKline;   University of Nebraska
Recruiting - verified January 2010

Conditions:   Liver Transplantation;   Hepatitis B;   Liver Disease
Intervention:   Drug: Entecavir
Sponsors:   HepNet Study House, German Liverfoundation;   HepNet Study House, German Liverfoundation;   Hannover Medical School
Recruiting - verified April 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: peginterferon alfa-2a [Pegasys];   Drug: COPEGUS
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Chronic Hepatitis C;   Oxidative Stress
Interventions:   Dietary Supplement: silymarin;   Dietary Supplement: green tea extract (EGCG)
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   National Center for Complementary and Alternative Medicine (NCCAM);   National Institutes of Health (NIH)
Recruiting - verified November 2011

Conditions:   HIV Infections;   Hepatitis C Virus
Intervention:  
Sponsors:   Rockefeller University;   Rockefeller University
Recruiting - verified February 2012

Conditions:   HIV Infection;   Liver Failure;   Liver Transplantation
Intervention:   Drug: Raltegravir potassium
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   French National Agency for Research on AIDS and Viral Hepatitis;   Merck
Recruiting - verified December 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: IFN alfa-2b XL 27 MUI + Ribavirin;   Drug: IFN alfa-2b XL 36 MUI + Ribavirin;   Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   French National Agency for Research on AIDS and Viral Hepatitis
Recruiting - verified February 2012

Conditions:   Hepatitis C;   Alcohol Use Disorders
Interventions:   Drug: baclofen;   Drug: placebo
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Recruiting - verified January 2012

Condition:   Hepatitis C
Interventions:   Drug: MK-5172;   Drug: Placebo
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Drug: Midazolam;   Drug: BMS-791325
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Not yet recruiting - verified February 2012

Condition:   Hepatitis B
Interventions:   Drug: Simvastatin;   Drug: Tenofovir;   Drug: Entecavir
Sponsors:   Bader, Ted, M.D.;   Bader, Ted, M.D.
Recruiting - verified June 2011

Conditions:   Nevirapine Induced Rash;   Nevirapine Induced Hepatitis;   HIV;   Adverse Side Effects;   AIDS;   HIV Infections
Interventions:   Genetic: Genetic test for NVP induced rash;   Other: 3TC/D4T/NVP or 3TC/AZT/NVP
Sponsors:   Mahidol University;   Mahidol University;   Department of Medicine,Ramathibodi Hospital;   Chulalongkorn University;   Bamrasnaradura Institute, Ministry of Public Health;   Thammasat University;   Department of Preventive Medicine,Srinakharinwirot University;   Chiang Rai Hospital;   Maharaj Nakornratchasima Hospital;   Department of Internal Medicine,Sawanpracharak Hospital;   Department of Internal Medicine,Burirum Hospital;   Department of Internal Medicine,Nakornping Hospital;   National Institute of Health, Department of Medical Sciences;   Clinical Research Center,Ministry of Public Health;   RIKEN
Recruiting - verified July 2010

Condition:   Chronic Hepatitis B
Intervention:   Drug: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified September 2009

Condition:   Chronic Hepatitis B
Intervention:  
Sponsors:   Chang Gung Memorial Hospital;   Chang Gung Memorial Hospital
Recruiting - verified March 2010

Condition:   Asymptomatic Chronic HCV Carriers
Intervention:   Drug: Bovine Colostrum Powder
Sponsors:   Hadassah Medical Organization;   Hadassah Medical Organization
Not yet recruiting - verified June 2011

Condition:   Hepatitis C Virus
Interventions:   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: BMS-791325;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Not yet recruiting - verified February 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Vaniprevir (600 mg b.i.d.);   Drug: Vaniprevir (300 mg b.i.d.);   Drug: Pegylated interferon (Peg-IFN);   Drug: Ribavirin (RBV)
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified July 2011

Condition:   Hepatitis B, Chronic
Interventions:   Drug: peginterferon alfa-2a [Pegasys];   Drug: Adefovir;   Drug: Entecavir;   Drug: Placebo
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   Hepatitis B, Chronic
Intervention:   Drug: peginterferon alfa-2a [Pegasys]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Carcinoma, Hepatocellular;   Liver Cirrhosis, Alcoholic;   Hepatitis, Alcoholic;   Hepatitis, Chronic;   Hepatitis, Viral, Human
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Chronic Hepatitis B
Intervention:   Drug: LDT600 (Telbivudine)
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Conditions:   HIV Infections;   Hepatitis C
Interventions:   Drug: Alcohol;   Drug: Alcohol placebo
Sponsors:   University of California, San Francisco;   University of California, San Francisco
Recruiting - verified April 2012

Condition:   Rift Valley Fever
Intervention:   Biological: Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Sponsors:   U.S. Army Medical Research and Materiel Command;   U.S. Army Medical Research and Materiel Command
Recruiting - verified January 2012

Condition:   Chronic Hepatitis C
Interventions:   Drug: Ribavirin;   Drug: Colchicine
Sponsors:   Hospital Universitario Ramon y Cajal;   Hospital Universitario Ramon y Cajal
Recruiting - verified May 2012

Conditions:   Hepatitis C, Chronic;   Cognition Disorders;   Fatigue Syndrome, Chronic;   Major Depressive Disorder
Interventions:   Drug: Interferon and ribavirin;   Drug: Interferon Alfa-2a + ribavirin
Sponsors:   University of Aarhus;   Aarhus University Hospital
Recruiting - verified December 2011

Conditions:   Acute Hepatitis A;   Acute Hepatitis B;   Acute Hepatitis C;   Acute Hepatitis E;   Acute EBV Hepatitis;   Acute CMV Hepatitis
Interventions:   Dietary Supplement: Silymarin;   Dietary Supplement: Silymarin;   Other: Lactose monohydrate
Sponsors:   University of Maryland;   University of Maryland;   MADAUS GmbH;   The Egyptian Company for Blood Transfusion Services (EgyBlood);   Tanta Fever Hospital;   Banha Fever Hospital;   Alexandria University
Recruiting - verified August 2011

Conditions:   Poliomyelitis;   Haemophilus Influenzae Type b Disease;   Hepatitis B;   Diphtheria;   Pertussis;   Tetanus
Intervention:   Biological: Infanrix™ hexa
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified August 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: Peginterferon;   Drug: Ribavirin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011

Conditions:   Hepatitis B;   Liver Transplantation
Intervention:   Biological: HepaGam B
Sponsors:   Cangene Corporation;   Cangene Corporation
Recruiting - verified April 2012

Condition:   Hepatitis C
Intervention:   Behavioral: Integrated care model
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs
Recruiting - verified January 2012

Condition:   Hepatitis C, Chronic
Interventions:   Procedure: Liver Biopsy;   Drug: Peginterferon & Ribavirin for Hepatitis C;   Drug: Pre-treatment Ribavirin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2012

Condition:   Dengue Fever
Intervention:   Genetic: CLEC5A
Sponsors:   Kaohsiung Medical University Chung-Ho Memorial Hospital;   Kaohsiung Medical University Chung-Ho Memorial Hospital;   Centers for Disease Control and Prevention
Recruiting - verified December 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: ribavirin;   Drug: ribavirin
Sponsors:   Foundation for Liver Research;   Foundation for Liver Research;   Hoffmann-La Roche
Recruiting - verified February 2012

Conditions:   Chronic Hepatitis C;   Atherosclerosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   University Hospital, Strasbourg, France;   University Hospital, Strasbourg, France
Recruiting - verified August 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: pegylated interferon alpha 2a and plus ribavirin;   Drug: Pegylated interferon alfa-2a and ribavirin;   Drug: pegylated interferon alpha 2a and ribavirin;   Drug: pegylated interferon alpha 2a and ribavirin
Sponsors:   Kaohsiung Medical University Chung-Ho Memorial Hospital;   Kaohsiung Medical University Chung-Ho Memorial Hospital
Recruiting - verified April 2012

Conditions:   Chronic Hepatitis B e Antigen Positive;   Chronic Hepatitis B e Antigen Negative
Intervention:   Drug: Tenofovir/ & Emtricitabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011

Condition:   Chronic Hepatitis C
Interventions:   Drug: Peg-interferon alpha 2a and ribavin;   Drug: ribavirin with adaptation dose
Sponsors:   Hospices Civils de Lyon;   Hospices Civils de Lyon
Recruiting - verified January 2012

Condition:   Hepatitis C
Intervention:   Drug: Ribavirin
Sponsors:   Maastricht University Medical Center;   Maastricht University Medical Center;   Roche Pharma AG
Recruiting - verified July 2011

Condition:   Hepatitis C, Chronic
Intervention:   Drug: peginterferon alfa-2a [Pegasys]
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Condition:   HIV Infections
Interventions:   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Bill and Melinda Gates Foundation
Recruiting - verified May 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   Rockefeller University;   Rockefeller University;   New York Presbyterian Hospital
Recruiting - verified April 2012

Condition:   Hepatitis B, Chronic
Intervention:   Drug: Entecavir
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified October 2011

Conditions:   Iron Overload;   Metabolic Syndrome X;   Hepatitis B;   Hepatitis C;   Alcohol Abuse
Intervention:   Device: Magnetic resonance imaging multiecho gradient-echo sequence
Sponsors:   Rennes University Hospital;   Rennes University Hospital;   Ministry of Health, France
Recruiting - verified February 2012

Condition:   Hepatitis C Virus Infection
Interventions:   Drug: Interferon injections and ribavirin;   Drug: Interferon injections and ribavirin
Sponsors:   University of British Columbia;   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified November 2011

Conditions:   Biliary Liver Cirrhosis,;   Hemochromatosis;   Hepatitis;   Hepatolenticular Degeneration;   Liver Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011

Condition:   Liver Fibrosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Condition:   Hepatitis C Virus
Intervention:  
Sponsors:   Rockefeller University;   Rockefeller University;   National Institute of Allergy and Infectious Diseases (NIAID);   New York Presbyterian Hospital
Recruiting - verified May 2012

Conditions:   Birth Defects;   Pregnancy Complications;   Hepatitis C
Intervention:  
Sponsors:   INC Research;   INC Research;   Aurobindo;   Genentech;   Sandoz Inc.;   Merck;   Teva Pharmaceuticals USA;   Kadmon Pharmaceuticals, LLC;   Zydus Pharmaceuticals USA, Inc.
Recruiting - verified October 2011

Conditions:   Hepatitis C;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Condition:   Virus Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified May 2012

Condition:   Hepatitis C
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011

Condition:   Hepatitis C
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified January 2012